J&J firms up Caplyta's 1st phase 3 win in bipolar-associated manic episodes

As Johnson & Johnson’s $14.6 billion bet on Intra-Cellular Therapies continues to pay off with blockbuster sales of Caplyta, the atypical antipsychotic has passed a phase 3 test that puts it one step closer to a broader psychiatric label.